Fingerprint
Dive into the research topics of 'A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically